Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy Authors: Zichen Pan, Fusheng Zhang, Cuixia Zhang, Xingyue Li, Yongsu Ma, Yinmo Yang, Xiaodong Tian Published: 2026 ABSTRACT SummaryPancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by a profoundly immunosuppressive tumor microenvironment (TME) that limits response to immunotherapy. Tumor-infiltrating B cells (TIBs) constitute a key TME component, and in certain patient subsets, they collaborate with T cells, dendritic cells, and other immune cells to form tertiary lymphoid structures (TLSs). Current evidence reveals functionally distinct TIB subsets in PDAC; while some subsets promote tumor progression, others enhance anti-tumor immunity. Therefore, comprehensively elucidating these dualistic roles is imperative. Concurrently, the presence of mature TLSs within PDAC correlates with improved prognosis and therapeutic outcomes. Understanding TIB and TLS dynamics, along with their interactions with other TME components, may unveil novel strategies to overcome immune suppression in PDAC. This review synthesizes recent advances in TIB and TLS research, evaluates their prognostic significance, and explores potential clinical applications. Introduction Pancreatic cancer ranks among the most lethal malignancies, accounting for 2.6% of all cancer cases globally yet contributing disproportionately to 4.8% of cancer-related deaths.1 This grim reality is reflected in its persistently poor prognosis, with a global 5-year survival rate of only 13%, alongside a concerning rise in incidence.2,3,4 Despite advances in surgical techniques, cytotoxic chemotherapy, and targeted therapies over recent decades, treatment outcomes remain suboptimal, as most patients experience recurrence within 18 months.5,6 Although immunotherapy, particularly immune checkpoint inhibitors, has revolutionized treatment for several other cancers,7 only a small subset of pancreatic cancer patients with mismatch repair deficiency derive clinical benefit.8 A key driver of this resistance is the profoundly immunosuppressive tumor microenvironment (TME), characterized by dense fibrotic stroma and extensive infiltration of immunosuppressive cells.9 Tumor-infiltrating B cells (TIBs) are present across multiple cancer types and constitute a key component of the pancreatic TME.10,11,12 Although T cells serve as primary mediators of anti-tumor immunity, they frequently become exhausted or anergic within tumors.13 TIBs commonly co-localize with T cells in the TME and share chemokine recruitment pathways with T cells and natural killer (NK) cells.14 Moreover, TIB infiltration levels correlate with the abundance and subtypes of cancer-associated fibroblasts (CAFs) as well as collagen expression.15,16 These findings indicate that TIBs broadly interact with other cellular and stromal TME components, potentially shaping its fundamental characteristics. In pancreatic liver metastases, tumor cells recruit TIBs to disrupt local immunity, suggesting TIB involvement in establishing pre-metastatic niches.17 Notably, subsets of pancreatic ductal adenocarcinoma (PDAC) patients exhibit TIB aggregation with T cells, dendritic cells, and other immune cells forming tertiary lymphoid structures (TLSs)—localized immune niches within the TME.18 TIBs and TLSs demonstrate functional duality in PDAC. Regulatory B cells (Bregs) foster immunosuppression through cytokine secretion,19 whereas other TIB subsets exert anti-tumor effects via antigen presentation, antibody production, TLS facilitation, and immune cell crosstalk within these structures.20,21 Comprehensive comprehension of TIB and TLS roles may inform immune subtyping, prognostic refinement, and strategies to overcome immunosuppression. This review synthesizes current knowledge on TIBs and TLSs in pancreatic cancer and highlights their translational potential. To structure this review, we conducted a comprehensive search of the PubMed database for articles published up to October 2025. The primary query was structured as follows: (“B cell∗ˮ OR “B lymphocyte∗” OR “B-lymphocyte∗ˮ OR “Plasma Cell∗ˮ OR “Regulatory B cell∗ˮ OR Breg∗ OR “Memory B cell∗ˮ OR “TLS” OR “tertiary lymphoid structure∗ˮ) AND (“pancreatic cancer” OR “pancreatic neoplasm∗ˮ OR “pancreatic carcinoma∗ˮ OR “pancreatic tumor∗ˮ OR “Pancreatic Ductal Adenocarcinoma” OR PDAC). Following the initial search, a manual screening of titles and abstracts was performed. Inclusion criteria were studies that directly investigated the biological roles, spatial distribution, prognostic value, or therapeutic implications of TIB or TLS specifically in pancreatic cancer. Subsets and features of TIBs in pancreatic cancer B cells arise in the bone marrow and migrate to peripheral tissues upon maturation to execute their functions. The canonical flow cytometry gating strategy classifies B cells into five sequential developmental stages based on maturation status: transitional B cells (CD19+CD24ʰiCD38ʰi), naive B cells (CD19+IgD+CD38−CD27−), non-switched memory B cells (CD19+CD27+IgD+), switched memory B cells (CD19+CD27+IgD−), and plasma cells (CD19+CD27+CD38+CD20−).22,23 As early as the 1980s, studies reported associations between B cells, antibodies, tumor development, and anti-tumor immunity.24,25,26,27 However, the role of B cells in pancreatic cancer remained largely overlooked for decades. Recent studies have revealed the clonal expansion and differentiation of TIBs.28,29 Current research has now identified some principal B cell subsets in PDAC. These subsets are outlined and discussed in detail below (Figure 1).Figure 1B cell subsets in PDACImmunosuppressive subsets including IL-10+ Bregs and IL-35+ Bregs have been extensively characterized. Elevated infiltration of naive B cells and memory B cells is observed in patients with favorable prognosis, though the underlying mechanisms require further investigation. Plasma cells may mediate anti-tumor immunity through antibody production. IL-17F+ B cells, BTLA+CD200+ B cells, and PD-L1+ B cells exhibit immunosuppressive functions. NK, natural killer cell; Treg, regulatory T cell; Breg, regulatory B cell; TAM, tumor-associated macrophage; PC, plasma cell; PDAC, pancreatic ductal adenocarcinoma. B cell subsets in PDAC Immunosuppressive subsets including IL-10+ Bregs and IL-35+ Bregs have been extensively characterized. Elevated infiltration of naive B cells and memory B cells is observed in patients with favorable prognosis, though the underlying mechanisms require further investigation. Plasma cells may mediate anti-tumor immunity through antibody production. IL-17F+ B cells, BTLA+CD200+ B cells, and PD-L1+ B cells exhibit immunosuppressive functions. NK, natural killer cell; Treg, regulatory T cell; Breg, regulatory B cell; TAM, tumor-associated macrophage; PC, plasma cell; PDAC, pancreatic ductal adenocarcinoma. Regulatory B cells Bregs, initially identified as an immunosuppressive subset in autoimmune enteritis and experimental autoimmune encephalomyelitis,30,31 are now widely reported in infections, autoimmune diseases, and tumors. Unlike regulatory T cells (Tregs), which are defined by the lineage-specific transcription factor Foxp3, Bregs lack a definitive transcription factor and are primarily characterized by their ability to secrete IL-10.32,33 Thus, Bregs likely do not represent a distinct lineage and cannot be classified within the canonical maturation-based B cell subsets mentioned above. A growing consensus suggests that any B cell possesses the potential to differentiate into a Breg phenotype under appropriate environmental stimuli.32,34,35 In both human and murine pancreatic cancer, several Breg subsets have been described. Human pancreatic tumors harbor CD19+CD38+36 Bregs, while murine models contain CD19+CD1dhiCD5+,37 CD19+CD1dhiCD5+CD21hi,38 and CD19+CD9+39 populations. In pancreatic cancer, most studies linking Bregs to an immunosuppressive microenvironment have focused on IL-35 rather than IL-10, the cytokine most often associated with these cells. Studies utilizing murine models have identified two distinct Breg subsets that secrete IL-35 and consequently impair anti-tumor immunity. These subsets are characterized as CD19+CD1dhiCD5+ and CD19+CD1dhiCD5+CD21hi. IL-35 is a heterodimer composed of p35 (Il12a) and Ebi3. Expression of Ebi3 is more tightly controlled than that of p35 and is considered the rate-limiting step in IL-35 production. Within the CD19+CD1dhiCD5+CD21hi subset, both subunits are highly expressed.40 Several signaling pathways drive the differentiation of IL-35-producing Bregs in PDAC. For example, IL-1β, via BTK, promotes the development of the CD19+CD1dhiCD5+ phenotype,41 while IL-35 secretion can be induced through STING-IRF3 signaling or the BCR-dependent PKD2 axis.42,43 Functionally, IL-35 drives tumor progression in preclinical murine models. In μMT mice reconstituted with B cells lacking either IL-35 or IL-10, tumor growth was inhibited only when IL-35 was absent, whereas IL-10 deficiency had no such effect.37 Mechanistically, IL-35 (1) engage STAT3 in gp130+CD8+ T cells, down-regulating CXCR3, CCR5, and IFN-γ to blunt cytotoxicity,44 (2) activate the STAT3-PAX5-BCL6 pathway in B cells, preventing plasma-cell differentiation and preserving the Breg phenotype,45 and (3) reduce NK cell cytotoxicity against target cells.42 Although early reports in PDAC indicated that IL-10 was dispensable for Breg-mediated tumor promotion,37 subsequent research has confirmed its immunosuppressive role. Zhu et al.36 demonstrated that CD38+CD19+ Bregs isolated from freshly resected PDAC tumors secrete IL-10, suppress NK cell cytotoxicity, and enhance Tregs infiltration. Furthermore, the transcription factor c-Maf has been identified as a driver of IL-10 production in a CD19+CD9+ Breg subset.39 Plasma cells and antibody responses Within the TME, naive B cells activated by antigens can differentiate into antibody-secreting plasma cells through either germinal center reactions or the extrafollicular pathway.29 These plasma cells and their secreted antibodies display significant heterogeneity in the TME. First, antibodies in the TME can exert anti-tumor effects through multiple mechanisms. On one hand, certain antibodies can internalize into tumor cells and directly target intracellular antigens or modulate critical signaling pathways to inhibit tumor progression.46,47 On the other hand, antibodies can mediate anti-tumor immunity by engaging Fc receptor-dependent effector functions, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP), and antibody-dependent cell-mediated cytotoxicity (ADCC).48 Conversely, accumulating evidence suggests that antibodies within the TME may also contribute to pro-tumorigenic processes under specific contexts. For instance, certain antibody subclasses or immune complexes may promote tumor metastasis or facilitate the remodeling of the TME toward an immunosuppressive and pro-angiogenic state, thereby supporting tumor immune evasion and progression.49,50 Antibody profiles exhibit substantial heterogeneity across different solid tumors. In the context of PDAC, Meng et al.51 demonstrated that TIBs produce IgG targeting mutant KRAS (the most frequently mutated gene in PDAC, with activating mutations observed in approximately 90% of patients52). This finding indicates the presence of an adaptive humoral immune response within the pancreatic TME. B cell receptor repertoire sequencing further uncovered elevated levels and diversity of IGH, IGK, and IGL transcripts in PDAC compared to normal pancreas, with abundant IGK+ cell infiltration correlating with improved prognosis.53 Notably, most antibodies detected in PDAC recognize broadly expressed self-antigens rather than tumor-specific epitopes. This frequent cross-reactivity with healthy tissues suggests that chronic inflammation expands pre-existing autoreactive B cell clones.54 Additionally, IgG4+ plasma cells release lysyl oxidase-like 2 (LOXL2), promoting stromal fibrosis.55 Evidence from ovarian and breast cancers indicates that serum autoantibodies do not consistently mirror those in the TME,56,57 which underscores the need to map antigen recognition in PDAC for deeper insights into local humoral immunity. Other B cell subsets Beyond Bregs and plasma cells, PDAC harbors additional TIB subsets that modulate tumor progression. Specifically, these subsets include non-Breg suppressive B cells, naive B cells, and memory B cells. Conventional Bregs are defined by IL-10 secretion; however, several B cell populations lacking this cytokine still exhibit potent pro-tumor functions. For instance, the pro-inflammatory cytokine IL-17 is primarily derived from Th17 cells within the TME. Depending on factors such as tumor type, developmental stage, and local microbiota, IL-17 exerts a complex dual role, acting as either tumor-promoting or tumor-suppressive.58 In murine models of PDAC, Chandra et al.59 demonstrated that genetic ablation of IL-17RA disrupts gut microbiota and is associated with the accumulation of a distinct IL-17F-secreting B cell subset in tumors. In this specific model, the released IL-17F signals via DUOX2 to accelerate tumor growth. In addition to the aforementioned subsets, Diskin et al.17 identified that pancreatic tumor cells in liver metastases induce BTLA+CD200+ B cells through IL-18. These cells promote tumor-associated macrophage differentiation, suppress T cell activation, and contribute to immunotherapy resistance. Corroborating this, research in non-neoplastic diseases suggests that B cell-expressed CD200 possesses the capacity to induce Tregs and suppress pro-inflammatory macrophages, which are mechanisms that parallel the conventional Breg-mediated immunosuppression.60,61 Furthermore, PD-L1 is a critical molecule mediating tumor immune evasion, with high PD-L1-expressing B cell subsets identified in malignancies such as melanoma and breast cancer.62 In PDAC, Tong et al.63 reported that PD-L1 expressing B cells inhibit IFN-γ release and CD8+ T cell proliferation, thereby facilitating immune escape. Taken together, research on non-Breg suppressive B cells in PDAC remains in its infancy. The specific cellular subtypes, underlying molecular mechanisms, and their clinical prevalence in PDAC patients warrant further investigation. Naive B cells represent antigen-inexperienced populations. Across multiple prognostic models stratifying patients by risk, tumors in low-risk groups consistently demonstrate elevated infiltration of naive B cells.64,65,66 Zhang et al.67 identified a twelve-gene signature associated with the CD38-CD27- naive subset that independently predicts favorable outcomes in PDAC. Memory B cells rapidly differentiate into antibody-secreting plasma cells or function as antigen-presenting cells, mediating long-term anti-tumor surveillance. van Eijck et al.68 observed significantly elevated memory B cells within the TME of long-term PDAC survivors after initial treatment, while Huang et al.69 further demonstrated that tumors enriched for FCGR2A-expressing memory B cells correlate with improved prognosis. Regulation of TIBs in the TME The TME comprises diverse components, including immune and stromal cells, cytokines, extracellular matrix (ECM) proteins, and intratumoral microbiota, all capable of regulating TIBs. This section focuses on summarizing recent advances in the regulatory mechanisms governing B cell recruitment and differentiation in pancreatic cancer (Figure 2).Figure 2Multiple factors influence TIB recruitment and differentiation in PDACDuring early tumor development, loss of Hif-1α and activation of IL-1β signaling enhances CXCL13 expression, promoting TIB recruitment. Conversely, in advanced PDAC, combined KRAS and moderate MYC activation alongside PD-1/PD-L1 signaling suppresses CXCL13 expression, limiting TIB infiltration. Furthermore, depletion of ASC-like CAFs promotes TIB recruitment, whereas depletion of myCAFs has the opposite effect. Microbial dysbiosis caused by IL-17RA deficiency enhances IL-17+ B cell infiltration into PDAC, while intratumoral microbiota associated with clinically poor prognosis correlates with reduced memory B cell infiltration. Additionally, loss of Col1 may impair B cell recruitment and function, and elevated TGF-β levels also correlate with reduced B cell infiltration. Regarding TIB differentiation, IL-18 promotes differentiation into IL-10+PD-L1+ Bregs and, specifically in liver metastases, into BTLA+CD200+ immunosuppressive B cells. IL-1β drives TIB differentiation toward CD19+CD1dhiCD5+ Bregs and PD-L1+ immunosuppressive B cells, and furthermore promotes anti-inflammatory IgG4 secretion. PD-1/PD-L1 signaling inhibits TIB differentiation into plasma cells and suppresses antibody secretion. Multiple factors influence TIB recruitment and differentiation in PDAC During early tumor development, loss of Hif-1α and activation of IL-1β signaling enhances CXCL13 expression, promoting TIB recruitment. Conversely, in advanced PDAC, combined KRAS and moderate MYC activation alongside PD-1/PD-L1 signaling suppresses CXCL13 expression, limiting TIB infiltration. Furthermore, depletion of ASC-like CAFs promotes TIB recruitment, whereas depletion of myCAFs has the opposite effect. Microbial dysbiosis caused by IL-17RA deficiency enhances IL-17+ B cell infiltration into PDAC, while intratumoral microbiota associated with clinically poor prognosis correlates with reduced memory B cell infiltration. Additionally, loss of Col1 may impair B cell recruitment and function, and elevated TGF-β levels also correlate with reduced B cell infiltration. Regarding TIB differentiation, IL-18 promotes differentiation into IL-10+PD-L1+ Bregs and, specifically in liver metastases, into BTLA+CD200+ immunosuppressive B cells. IL-1β drives TIB differentiation toward CD19+CD1dhiCD5+ Bregs and PD-L1+ immunosuppressive B cells, and furthermore promotes anti-inflammatory IgG4 secretion. PD-1/PD-L1 signaling inhibits TIB differentiation into plasma cells and suppresses antibody secretion. Recruitment of TIBs Current research on TIB recruitment in pancreatic cancer focuses predominantly on CXCL13. Pylayeva-Gupta et al.37 first implicated CXCL13 in promoting early tumor progression by recruiting Bregs. Multiple pathways modulate CXCL13 expression to regulate TIB recruitment. First, during early tumorigenesis in LSL-Kras+/G12D; Pdx1-Cre (KC) mice, experimental overexpression of IL-1β was shown to induce tumor cell-derived CXCL13 secretion, recruiting immunosuppressive B cells which is associated with accelerated tumor growth.70 Second, in advanced tumors, KRAS activation with moderate MYC elevation reduces macrophage-derived CXCL13, diminishing B cell recruitment and enhancing immune evasion.71 Third, the PD-L1/PD-1 axis suppresses CXCL13 secretion by follicular helper T cells (Tfh), blocking B cell recruitment and limiting antitumor immunity.72 Beyond cellular components, hypoxia influences B cell infiltration.73 In murine models, Hif-1α deficiency increases chemokine expression (primarily CXCL13), enhancing B cell recruitment.74 Interestingly, in studies of epithelial-derived tumors, TGF-β-dependent CD103+CD8+ tumor-infiltrating T cells have been shown to secrete CXCL13, a process closely associated with B cell recruitment and TLS formation.75 This observation contradicts the conventional immunosuppressive role of TGF-β. Taken together, these findings establish CXCL13 as a central regulator of TIB recruitment in pancreatic cancer, while underscoring that its impact on tumor progression differs substantially based on B cell subsets, tumor stage, and model context. Beyond CXCL13-mediated recruitment, CAFs, as key regulators of the TME, modulate TIBs. Based on transcriptional profiles, functional characteristics, and spatial localization, CAFs can be classified into three major subsets: myofibroblastic CAFs (myCAFs), inflammatory CAFs (iCAFs), and antigen-presenting CAFs (apCAFs).76 Subsets of CAFs differentially regulate TIB dynamics. Using a transgenic murine model, Özdemir et al.77 first demonstrated that myCAF depletion reduces B cell infiltration and correlates with poor prognosis. Conversely, a novel adipose tissue-derived CAF subset (ASC-like CAFs) exerts opposing effects, as their depletion increases B cell infiltration.78 Moreover, tumor cell-derived IL-1β induces CAFs to secrete CCL2, CCL5, and CCL12, thereby recruiting Bregs.79 Overall, these findings demonstrate that distinct CAF subsets differentially modulate B cell recruitment during pancreatic cancer progression. However, the precise underlying mechanisms governing these interactions remain to be fully elucidated. PDAC features a highly fibrotic stroma, where collagen content correlates with B cell recruitment. Ashina et al.80 observed reduced TLS frequency in tumors with low stromal collagen. Similarly, genetic ablation of Col1 has been linked to the recruitment of myeloid-derived suppressor cells (MDSCs), which may contribute to impaired B cell recruitment and function.15 Notably, shorter-surviving PDAC patients exhibit elevated TGF-β levels, correlating with α-SMA-rich dense stroma and diminished B-cell infiltration.81 Furthermore, IL-17RA disruption induces dysbiosis, promoting IL-17+ B cell infiltration,59 while poor-prognosis intratumoral microbiota correlates with reduced memory B cells.82 Collectively, stromal components differentially regulate B cell recruitment in PDAC, whereas microbiota-mediated influences are emerging and require further investigation. Differentiation of TIBs in the TME Beyond recruitment, the pancreatic TME critically shapes B cell differentiation post-infiltration. Mechanistic insights into TIB differentiation remain limited, with IL-18, IL-1β, and Tfh being the primary regulators identified. Tumor-derived IL-18 drives B cell differentiation toward IL-10+PD-L1+ Bregs, suppressing antitumor immunity.83 Similarly, IL-18ʰi PDAC cells induce BTLA+CD200+ immunosuppressive B cells in hepatic metastases.17 For IL-1β, KRASᴳ12ᴰ-mutant pancreatic epithelial cells promote a specific murine Breg subset (CD19+CD1dʰiCD5+) and PD-L1+ B cells via IL-1β signaling.70 Additionally, IL-1β functions as an upstream initiator rather than a direct polarizer to drive Tfh2 differentiation. These Tfh2 cells then secrete IL-13, which is implicated in stimulating anti-inflammatory IgG4 production in B cells while suppressing pro-inflammatory IgE via the PGE2–EP4 axis.84 Likewise, Tfh secrete IL-21 to promote plasma cell differentiation and IgG/IgM production, a process suppressible by PD-L1/PD-1 signaling.72 TLSs in pancreatic cancer In a subset of PDAC patients, TIBs cooperate with other immune constituents to assemble TLSs within the TME. TLSs are ectopic immune cell aggregates that develop in non-lymphoid tissues, serving as functional sites for antitumor immune responses.85 The location, density, and maturation stage of TLSs correlate significantly with TIB abundance, spatial distribution, functional states, and PDAC patient prognosis.86 The following section focuses on TLSs in pancreatic cancer, addressing their formation, distribution, maturation, and functional roles. Composition and formation of TLSs TLSs resemble secondary lymphoid organs (SLOs) in structure, containing a B cell zone with germinal centers, a T cell zone, high endothelial venules (HEVs), and dendritic cells that function as antigen-presenting sites.87 Unlike SLOs, TLSs lack a fibrous capsule as well as afferent or efferent lymphatic vessels.88 The absence of a defined encapsulated structure is thought to facilitate direct interaction between immune cells within TLSs and local antigens, potentially enhancing site-specific immune responses. Building on early findings that TLSs and SLOs share developmental pathways, emerging evidence reveals that TLS formation in chronic inflammation is driven by lymphoid tissue inducer (LTi) cells; these cells activate lymphoid tissue organizer (LTo) cells via LTα1β2–LTβR signaling to trigger the localized expression of adhesion molecules and chemokines.86,89 Beyond the LTi-LTo axis, a permissive tissue microenvironment is indispensable for TLS formation. Evidence suggests that the targeted depletion of Tregs can promote the neogenesis of HEVs, thereby potentially facilitating TLS assembly.90,91 However, most of the above-mentioned studies on TLS formation mechanisms derive from autoimmune and chronic inflammatory models, with mechanisms in the TME remaining incompletely understood.86 Despite this, LTα1β2–LTβR-dependent pathways for TLS neogenesis do exist in PDAC; for instance, Amisaki et al.92 demonstrated that IL-33 activates gut-derived LT+ ILC2 cells, stimulating LTβR+ myeloid cells via lymphotoxin signaling to produce CXCL13, thereby recruiting B cells. Interestingly, accumulating evidence indicates that TLS formation can also proceed independently of LTα1β2–LTβR signaling across various malignancies.93,94,95 Consistent with this, alternative mechanisms have been identified in PDAC, where CAFs secrete TGF-β to induce CXCL13+ T cells, which subsequently recruit B cells through CXCL13-dependent pathways to initiate TLS assembly.85 Similarly, recent studies have revealed complex bidirectional interactions between nervous system and tumors, which play critical roles in tumorigenesis and progression, leading to the emergence of cancer neuroscience as a distinct field.96,97 In PDAC, neural invasion, a hallmark of the disease may correlate with TLS development. Nerve fibers in PDAC frequently colocalize with TLSs,98 a process potentially mediated by APOD-enriched fibroblasts located within the endoneurium. These fibroblasts act as LTo cells, promoting TLS assembly via the CXCL12-dependent recruitment of CXCR4+ B cells.99 In PDAC, non-invaded nerves exhibit a higher propensity to colocalize with TLSs. This preferential association is likely attributable to the highly immunosuppressive perineural niche of invaded nerves, characterized by the enrichment of myCAFs, NLRP3+ macrophages, and inhibitory cytokines such as IL-10 and TGF-β.99 Genetic background also modulates TLS formation: Kras-G12D and TP53 mutations correlate with TLS absence,100,101 while mutations in DNA repair genes (e.g., ATM and STK11) are associated with enhanced TLS development.102 Recent advances in the mechanisms underlying TLS formation in PDAC are summarized in Figure 3A.Figure 3Development and classification of TLSs in PDAC(A) Mechanisms underlying TLS formation in PDAC. In PDAC, TLS formation may be promoted by CAF-derived TGF-β through the induction of CXCL13⁺ T cells, by IL-33–activated ILC2s, and by CXCL12 signals associated with non-invaded nerves. TLS development is also influenced by genetic background, with Kras-G12D and TP53 alterations associated with TLS absence and DNA repair gene mutations, such as ATM and STK11, associated with enhanced TLS formation.(B) Classification of TLSs based on: (1) location: intratumoral (within tumor parenchyma) or peritumoral (adjacent to tumor margin); (2) lymphoid aggregates, immature TLSs, or mature TLSs (with germinal centers). Notably, mature TLSs are not uniformly beneficial. Their functional plasticity, ranging from an active anti-tumor phenotype to a suppressed state, is driven by internal cellular composition. Development and classification of TLSs in PDAC (A) Mechanisms underlying TLS formation in PDAC. In PDAC, TLS formation may be promoted by CAF-derived TGF-β through the induction of CXCL13⁺ T cells, by IL-33–activated ILC2s, and by CXCL12 signals associated with non-invaded nerves. TLS development is also influenced by genetic background, with Kras-G12D and TP53 alterations associated with TLS absence and DNA repair gene mutations, such as ATM and STK11, associated with enhanced TLS formation. (B) Classification of TLSs based on: (1) location: intratumoral (within tumor parenchyma) or peritumoral (adjacent to tumor margin); (2) lymphoid aggregates, immature TLSs, or mature TLSs (with germinal centers). Notably, mature TLSs are not uniformly beneficial. Their functional plasticity, ranging from an active anti-tumor phenotype to a suppressed state, is driven by internal cellular composition. Distribution of TLSs The distribution of TLSs represents key characteristics in PDAC that correlate significantly with patient prognosis.18,85 Current studies distinguish between intratumoral (within tumor parenchyma) and peritumoral (adjacent to tumor margin) TLSs, with the intratumoral phenotype being substantially rarer.18,100 Tumors harboring intratumoral TLSs exhibit enhanced Th1- and Th17-mediated immune responses, increased T and B cell infiltration, reduced FOXP3+ regulatory T cell proportions, and diminished vascular invasion.18 Clinically, the presence of intratumoral TLSs independently predicts improved overall survival and disease-free survival in specific cohorts.18 Notably, the intratumoral TLSs are almost exclusively confined to the tumor margins, demonstrating minimal infiltration into the nests themselves.103 The biological basis and clinical implications of this spatial restriction remain unclear. In summary, these findings indicate that TLS presence and anatomical positioning shape immunological activity and prognostic outcomes in PDAC (Figure 3B). Maturation status of TLSs Beyond spatial distribution, TLS maturation stage closely correlates with the TME. Histologically, TLS maturation divides into three stages: (1) lymphoid aggregates (stage one) comprise small aggregates of T cells, B cells, and occasional dendritic cells; (2) immature TLSs (stage two) exhibit segregated T and B cell zones with follicular dendritic cell (FDC) networks but lack germinal centers. (3) Mature TLSs (stage three), defined by active germinal centers, enable lymphocyte activation and proliferation (Figure 3B).89 Beyond histology, recent pancreatic cancer studies leverage CD21/CD23 expression,104 and gene signatures (e.g., CD79A, CXCL13) to generate germinal center scores that quantify TLS maturation.85 Regarding the maturation process, Delvecchio et al.105 identified three precursor lymphoid aggregates in pancreatic cancer tissue: scattered T cells, T cell clusters, and mixed T/B cell aggregates lacking CD21+ FDCs, suggesting potential early stages of TLS development. Moreover, TLS maturation correlates with the tumor immune microenvironment composition. In PDAC, mature TLSs correlate with increased infiltration of naive B cells, NK cells, and CD8+ T cells.104,106 To sum up, these findings demonstrate the maturation state of TLSs not only reflects their structural organization but the immune landscape of PDAC. Functional roles of TLSs TLSs represent functional hubs for antigen presentation, adaptive immunity activation, and immune memory establishment.94 In PDAC, intratumoral TLSs correlate with increased T and B cell infiltration within the TME and improved patient outcomes.102,107,108 On the cellular immune level, TLSs are characterized by (1) a higher CD8:Treg ratio,87 (2) an increased presentation of MHCI-restricted neoantigens,106 and (3) the direct promotion of dendritic cell maturation by TLS-associated B cells, potentiating CD8+ T cell activation.105 Emerging evidence further implicates TLSs in restraining neural invasion via CD8+ T cell activity.99 Humoral immunity is enhanced in TLS-positive PDAC, evidenced by elevated BCR IgG1 class switching and somatic hypermutation rates in mature TLSs.106 Stromally, TLS-positive tumors exhibit reduced fibrosis.109 Regarding tumor dissemination, TLSs correlate with suppressed tumor budding, suggesting inhibition of EMT-like invasion.102 To summarize, these findings establish a multifunctional anti-tumor role for TLSs in PDAC. However, most evidence remains correlative, and mechanistic insights are still limited. TIBs and TLSs as potential prognostic biomarkers in pancreatic cancer Recent advances demonstrate pivotal roles of TIBs and TLSs in pancreatic cancer. Both emerge as key regulators of the tumor immune microenvironment, with emerging evidence establishing their clinical relevance to patient prognosis. In the following sections, we focus on detection methods, prognostic significance, and predictive value of TIBs/TLSs for treatment response in PDAC. Detection strategies Translating TIB/TLS research into clinical practice requires safe, practical, and efficient detection methods. Conventional TIB assessment relies on flow cytometry, transcriptome sequencing, and immunoimaging. TLSs are typically identified in resected specimens using hematoxylin-eosin staining, immunofluorescence, multiplex immunohistochemistry, RNA sequencing, or spatial transcriptomics.110 Beyond detection modalities, establishing standardized criteria to define TLS positivity is equally crucial for clinical application. Table 1 summarizes the reported incidence of intratumoral TLSs in PDAC and their prognostic implications. Given the substantial variability in reported TLS positivity rates across studies, we critically reviewed potential confounding factors, including the type of tissue analyzed, detection methodologies, specific criteria for defining TLS positivity, patient baseline characteristics, and prior treatment histories. These study-specific characteristics are also detailed in Table 1. Notably, we observed that the use of tissue microarrays (TMAs) is more prone to underestimating TLS incidence compared to whole-slide imaging.105 Furthermore, studies evaluating multiple tissue sections consistently report higher TLS detection rates.Table 1Proportion of intratumoral TLS-positive patients in PDAC studiesIntratumoral TLSs-positive/TotalPositive percentageMature TLSs distinguished (mature TLSs/total TLSs, percentage)TLS assessment criteria and cohort characteristicsAssociation between TLSs and prognosisReference80/38021.1%yes (51/80, 63.8%)method: ML-based digital analysis (inForm/HALO);cohort: NAT subgroup showed lower positivity (15.4%)the presence of TLSs is an independent prognostic factor for both OS (HR = 0.695) and PFS (HR = 0.709) (adjusted for age, TNM stage, grade, and vascular invasion). Patients with mature TLSs exhibit significantly better OS compared to those with other stages of TLS maturation.Zou et al.10429/6346.0%yes (9/29, 31.0%)sampling: 4–8 serial sections per patient;threshold: ≥2 TLSspatients with immature TLSs demonstrated significantly longer median OS (26.32 months vs. 14.37 months in TLS−; p = 0.014). Remarkably, mature TLS+ patients achieved a median OS of 56 months with a 50% 5-year survival rate.A et al.10649/30815.9%nosampling: largest cross-section;threshold: presence vs. absence;definition: boundary-located TLSs strictly classified as peritumoralpatients with intratumoral TLSs demonstrated significantly superior OS and DFS compared to patients without intratumoral TLSs (adjusted for tumor size, pathologic node status, pathologic metastasis status, grade, venous invasion, nerve plexus invasion, lymphatic invasion and intrapancreatic neural invasion).Hiraoka et al.1827/16216.7%nosampling: whole-slide section; threshold: presence vs. absenceTLSs serve as an independent prognostic factor for cancer specific survival (CSS). Patients with intratumoral TLSs demonstrate significantly superior CSS compared to those with peritumoral TLSs.Tanaka et al.10021/12017.5%nosampling: tissue microarray (TMA);threshold: presence vs. absencethe presence of TLSs is significantly associated with reduced tumor budding (p = 0.0011), prolonged OS (p < 0.0001) and improved DFS (p = 0.0067).Wartenberg et al.10223/6535.4%nosampling: whole-slide section; threshold: presence vs. absence;cohort: NAT status not explicitly specifiedTLS positive patients exhibited significantly reduced risk for OS (HR = 0.407, 95% CI 0.180–0.921, p = 0.031) and RFS (HR = 0.407, 95% CI 0.145–0.738, p = 0.007) (adjusted for N classification, AJCC stage, and tumor residual/R1 resection).Hu et al.10117/5530.9%nosampling: whole-slide section; threshold: presence vs. absenceTLS positive patients demonstrated significantly superior OS compared to TLS negative patients (p = 0.018).Ahmed et al.10813/31 (Whole-slide section)41.9%nosampling: TMA + whole-slide section;threshold: density ≥0.1 TLS/mm2TLS presence may be associated with improved prognosis and enhanced gemcitabine efficacy.Delvecchio et al.1059/1464.3%nosampling: two sections/tumor (>60 μm depth);threshold: presence vs. absenceTLS positive patients demonstrated a trend toward longer survival (median survival: 755 days vs. 478 days in TLS negative; HR = 0.15, 95% CI 0.02–1.19, p = 0.07).Stromnes et al.87Unless otherwise specified, the data in the “Intratumoral TLSs-positive/Total” column represent cohorts of patients who underwent upfront surgery without prior NAT. ∗ The treatment history for patients in ref.101 was not detailed.The core definition of TLS across the tabulated studies is: unencapsulated, ectopic lymphoid aggregates induced by chronic inflammation or tumors, which can mature into complex, lymph node-like structures containing distinct T/B-cell zones, HEVs, and germinal centers. Table 1Proportion of intratumoral TLS-positive patients in PDAC studiesIntratumoral TLSs-positive/TotalPositive percentageMature TLSs distinguished (mature TLSs/total TLSs, percentage)TLS assessment criteria and cohort characteristicsAssociation between TLSs and prognosisReference80/38021.1%yes (51/80, 63.8%)method: ML-based digital analysis (inForm/HALO);cohort: NAT subgroup showed lower positivity (15.4%)the presence of TLSs is an independent prognostic factor for both OS (HR = 0.695) and PFS (HR = 0.709) (adjusted for age, TNM stage, grade, and vascular invasion). Patients with mature TLSs exhibit significantly better OS compared to those with other stages of TLS maturation.Zou et al.10429/6346.0%yes (9/29, 31.0%)sampling: 4–8 serial sections per patient;threshold: ≥2 TLSspatients with immature TLSs demonstrated significantly longer median OS (26.32 months vs. 14.37 months in TLS−; p = 0.014). Remarkably, mature TLS+ patients achieved a median OS of 56 months with a 50% 5-year survival rate.A et al.10649/30815.9%nosampling: largest cross-section;threshold: presence vs. absence;definition: boundary-located TLSs strictly classified as peritumoralpatients with intratumoral TLSs demonstrated significantly superior OS and DFS compared to patients without intratumoral TLSs (adjusted for tumor size, pathologic node status, pathologic metastasis status, grade, venous invasion, nerve plexus invasion, lymphatic invasion and intrapancreatic neural invasion).Hiraoka et al.1827/16216.7%nosampling: whole-slide section; threshold: presence vs. absenceTLSs serve as an independent prognostic factor for cancer specific survival (CSS). Patients with intratumoral TLSs demonstrate significantly superior CSS compared to those with peritumoral TLSs.Tanaka et al.10021/12017.5%nosampling: tissue microarray (TMA);threshold: presence vs. absencethe presence of TLSs is significantly associated with reduced tumor budding (p = 0.0011), prolonged OS (p < 0.0001) and improved DFS (p = 0.0067).Wartenberg et al.10223/6535.4%nosampling: whole-slide section; threshold: presence vs. absence;cohort: NAT status not explicitly specifiedTLS positive patients exhibited significantly reduced risk for OS (HR = 0.407, 95% CI 0.180–0.921, p = 0.031) and RFS (HR = 0.407, 95% CI 0.145–0.738, p = 0.007) (adjusted for N classification, AJCC stage, and tumor residual/R1 resection).Hu et al.10117/5530.9%nosampling: whole-slide section; threshold: presence vs. absenceTLS positive patients demonstrated significantly superior OS compared to TLS negative patients (p = 0.018).Ahmed et al.10813/31 (Whole-slide section)41.9%nosampling: TMA + whole-slide section;threshold: density ≥0.1 TLS/mm2TLS presence may be associated with improved prognosis and enhanced gemcitabine efficacy.Delvecchio et al.1059/1464.3%nosampling: two sections/tumor (>60 μm depth);threshold: presence vs. absenceTLS positive patients demonstrated a trend toward longer survival (median survival: 755 days vs. 478 days in TLS negative; HR = 0.15, 95% CI 0.02–1.19, p = 0.07).Stromnes et al.87Unless otherwise specified, the data in the “Intratumoral TLSs-positive/Total” column represent cohorts of patients who underwent upfront surgery without prior NAT. ∗ The treatment history for patients in ref.101 was not detailed.The core definition of TLS across the tabulated studies is: unencapsulated, ectopic lymphoid aggregates induced by chronic inflammation or tumors, which can mature into complex, lymph node-like structures containing distinct T/B-cell zones, HEVs, and germinal centers. Proportion of intratumoral TLS-positive patients in PDAC studies Unless otherwise specified, the data in the “Intratumoral TLSs-positive/Total” column represent cohorts of patients who underwent upfront surgery without prior NAT. ∗ The treatment history for patients in ref.101 was not detailed. The core definition of TLS across the tabulated studies is: unencapsulated, ectopic lymphoid aggregates induced by chronic inflammation or tumors, which can mature into complex, lymph node-like structures containing distinct T/B-cell zones, HEVs, and germinal centers. In clinical practice, translating TIB and TLS detection into actionable biomarkers requires careful consideration of the available methodologies. Currently, tissue-based histological evaluation remains the gold standard, as it provides crucial spatial context. Furthermore, the integration of deep learning algorithms allows for the quantification of TLSs via weakly supervised learning,111 facilitating the establishment of objective technical standards and addressing the high variability in TLS positivity rates. However, tissue-based assays are inherently limited by their invasiveness and potential sampling bias due to intratumoral heterogeneity. Therefore, non-invasive or minimally invasive alternatives are highly desirable for clinical monitoring. For instance, CT and MRI radiomics offer a practical, non-invasive approach that captures whole-tumor heterogeneity, demonstrating potential in predicting intratumoral CD20+ B cell levels.112,113 Additionally, minimally invasive blood biomarkers are gaining traction. As the primary venous drainage site for pancreatic tumors, portal vein blood bypasses systemic dilution and exhibits a regional enrichment of tumor-infiltrating immune cells. To access this compartment, several studies have evaluated the safety of endoscopic ultrasound-guided portal vein sampling.114,115 Highlighting the diagnostic value of such samples, distinct research indicates that the frequencies of CD27+ memory B cells, Tregs, and PD-1+CD8+ T cells in portal vein blood correlate with their intratumoral abundance.116 Similarly, at the systemic level, reduced serum IL-2 has been associated with increased TLS formation, whereas routine parameters including C-reactive protein, white blood cell count, and CA19-9 have not demonstrated significant correlations.108 In conclusion, to translate these findings into practice, clinicians may benefit from a combinatorial approach: utilizing radiomics or blood-based biomarkers for dynamic, non-invasive screening, while reserving tissue-based deep learning evaluations for definitive spatial mapping. Prognostic significance Current evidence reveals substantial heterogeneity among TIB subtypes during tumor progression. In PDAC, elevated total B cell counts do not consistently correlate with prognosis,108,117,118 whereas higher infiltration of CD38+ B cells, naive B cell enrichment, and elevated immunoglobulin abundance with diverse clonal patterns, especially IGK-dominant clonotypes, are associated with favorable outcomes.36,53,67 Taken together, prognostic assessments of TIBs in PDAC should prioritize functional and phenotypic characteristics of specific subpopulations over total B cell quantification. In contrast to the uncertain prognostic value of total TIB abundance in pancreatic cancer, intratumoral TLSs consistently correlate with favorable outcomes.87,100,101,119,120 However, their precise prognostic and predictive value is highly dependent on their spatial localization and maturation stage. Specifically, intratumoral TLSs—rather than peritumoral ones—appear to be the primary drivers of enhanced survival. For instance, studies explicitly distinguishing these compartments show that patients with intratumoral TLSs demonstrate significantly superior survival compared to those with strictly peritumoral TLSs.18,100 Furthermore, distinguishing mature TLSs from total TLSs provides deeper prognostic insight. While the overall presence of TLSs is generally beneficial, the prognostic advantage is most pronounced in patients harboring mature TLSs. As detailed in Table 1, mature TLSs serve as an independent prognostic factor, and patients with mature TLSs can achieve a remarkable median overall survival of 56 months, compared to only 26.32 months for those with immature TLSs.106 Predictive value for therapeutic response Emerging studies demonstrate predictive value of TLSs for treatment response in pancreatic cancer.121 In PDAC, mature TLSs predict improved response to chemotherapy-nivolumab combination therapy.85 Similarly, TLS positivity correlates with enhanced efficacy of adjuvant S-1 chemotherapy.100 Prognostic models incorporating TLSs and naive B cells reveal differential chemotherapy sensitivity among patient subgroups.67,122,123 Although the evidence is still limited, TLS positivity has been shown to correlate with favorable therapeutic outcomes, especially for immunotherapy, in a spectrum of malignancies. This finding underscores the necessity of dedicated investigations within the context of PDAC.124 Potential therapeutic targeting of TIBs and TLSs in pancreatic cancer Beyond prognostic significance, current studies demonstrate therapeutic targeting potential of TIBs and TLSs in pancreatic cancer. Current strategies focus on suppressing immunosuppressive Bregs and inducing TLS maturation. These approaches are mechanistically discussed in subsequent sections. Strategies targeting pro-tumor Bregs Second part of this review outlined the immunosuppressive functions of Bregs in pancreatic cancer. Current therapeutic strategies focus on depleting intratumoral Bregs or neutralizing their protumor cytokines (Figure 4). For instance, CXCL13 blockade, which was validated in murine orthotopic PDAC models, has been shown to reduce Breg infiltration and tumor burden.37,125 This finding is consistent with the recognized role of CXCL13 in TIB recruitment. For existing intratumoral Bregs, inhibitors targeting BTK, PI3K-γ, or CD38 can reduce Breg populations and potentially interfere with myeloid crosstalk, exerting anti-tumor effects.36,41,126,127 Neutralizing Breg-derived cytokines represents another approach: anti-IL-35 antibodies were shown to restrain pancreatic intraepithelial neoplasia (PanIN)-to-PDAC progression in IL-1β-overexpressing models,70 suggesting that IL-35 may serve as a key tumor-promoting mediator.Figure 4B-cell targeting in PDAC: promise versus realityPreclinical studies demonstrate that blocking Breg recruitment to the tumor, depleting intratumoral Bregs, and neutralizing B cell-derived pro-tumor cytokines actively contribute to tumor suppression. However, in the B cell-targeted phase III RESOLVE trial, ibrutinib not only failed to improve OS or PFS, but conversely led to a shortened PFS. Potential reasons for this include shorter treatment cycles and lower cumulative drug doses in the ibrutinib cohort compared to the placebo group; the failure of preclinical models to adequately recapitulate the complex TME of human patients; and the lack of patient immunophenotyping based on indicators such as the presence of TLS in the clinical trial. B-cell targeting in PDAC: promise versus reality Preclinical studies demonstrate that blocking Breg recruitment to the tumor, depleting intratumoral Bregs, and neutralizing B cell-derived pro-tumor cytokines actively contribute to tumor suppression. However, in the B cell-targeted phase III RESOLVE trial, ibrutinib not only failed to improve OS or PFS, but conversely led to a shortened PFS. Potential reasons for this include shorter treatment cycles and lower cumulative drug doses in the ibrutinib cohort compared to the placebo group; the failure of preclinical models to adequately recapitulate the complex TME of human patients; and the lack of patient immunophenotyping based on indicators such as the presence of TLS in the clinical trial. Although Breg-targeted therapies show promise in preclinical studies, clinical trials yield less favorable outcomes. In the phase III RESOLVE trial combining ibrutinib with nab-paclitaxel/gemcitabine for metastatic PDAC, ibrutinib did not improve overall or progression-free survival (PFS) and even resulted in shorter PFS.128 The investigators attributed this lack of expected therapeutic efficacy to shorter treatment durations and lower cumulative drug doses in the ibrutinib arm compared to the placebo cohort.128 However, this translational failure necessitates a deeper analysis of its root causes, primarily concerning model limitations and the lack of patient immune subtyping. First, many preclinical studies demonstrating the efficacy of Breg depletion utilized orthotopic PDAC murine models. These models often fail to fully recapitulate the complex human TME, typically lacking substantial TIB infiltration, TLSs, or immunoglobulin deposition. In contrast, in KPC genetic models and human PDAC, TIBs exhibit marked functional heterogeneity and can exert robust anti-tumor effects.129 Second, the lack of baseline immune subtyping in clinical trials further compounds this issue. In patients with mature TLSs, B cells are predominantly involved in anti-tumor responses. Consequently, administering broad-spectrum B cell or BTK inhibitors without stratifying patients based on their baseline immune phenotypes risks indiscriminately depleting beneficial anti-tumor TIBs alongside pro-tumor Bregs, ultimately neutralizing the potential clinical benefit. Strategies promoting TLS formation and maturation Promoting TLS formation and maturation represents another therapeutic strategy (Table 2). In PDAC patients, neoadjuvant GVAX vaccination induces TLS development and its concurrent administration with nivolumab further augments the infiltration of anti-tumor T cells within TLSs while reducing the frequency of PD-1+ T cells, changes that are strongly associated with significant prognostic improvements.130,131 Intriguingly, the mere induction of TLS formation in PDAC might not translate to substantial prognostic benefits. The association between increased TLS density and improved outcomes appears consistently mediated by T cell alterations,131,132 implying that the anti-tumor efficacy of TLSs relies heavily on the remodeling of their internal immune microenvironment. Preclinically, IL-33 has been reported to promote TLS formation,92 while MLP-aTIM-3 treatment is associated with enhanced TLS formation and maturation.132 Interestingly, a CXCL13/CCL21 co-administration promotes TLS development in orthotopic PDAC models and synergizes with gemcitabine in TLS-positive mice.105 This finding contrasts with prior reports indicating that CXCL13 blockade reduces Breg infiltration and tumor burden.37,125 This functional dichotomy underscores the dual roles of TIBs in PDAC, highlighting the need for refined disease stratification and suggesting that targeting B cell downstream effectors may yield more precise therapies.Table 2TLS-based therapies for clinical applications in PDACSpeciesTreatmentFindingsReferenceHumanGVAXOf 39 patients, 33 (85%) developed TLS in their tumors 2 weeks after GVAX vaccination.Lutz et al.130HumanGVAX ± nivolumabwhile GVAX vaccination induced TLS formation, it provided only limited prognostic benefit. Subsequent nivolumab combination therapy substantially augmented anti-tumor CD4+/CD8+ T cell infiltration within TLSs, correlating strongly with enhanced patient survival.Li et al.131HumanSBRTfollowing SBRT, TLSs exhibited reduced overall quantity and dimensions. However, post-treatment TLSs demonstrated preferential localization within or immediately adjacent to tumor regions. Furthermore, these residual TLSs showed significant depletion of Tregs and PD-1+ CD8+ T cells.Mills et al.133MouseH-e-rIL-33–Fcsignificantly expanded intratumoral KLRG1+ ILC2s, promoting TLS formation and suppressing tumor growth.Amisaki et al.92MouseMLP-aTIM-3the MLP-aTIM-3 nano-vaccine effectively targets exhausted T cells, restores CD8+ T cell function through TIM-3 signaling blockade, and significantly promotes TLS neogenesis and maturation within TME. This therapeutic strategy demonstrated tumor growth suppression and prolonged survival in animal models.Chen et al.132MouseCXCL13 + CCL21in orthotopic PDAC murine models, combined CXCL13/CCL21 administration promoted de novo TLS formation. This combination strategy significantly enhanced survival outcomes compared to gemcitabine monotherapy.Delvecchio et al.105GVAX, an allogeneic PDAC vaccine engineered through irradiation to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF); SBRT, stereotactic body radiotherapy; H-e-rIL-33-Fc, the engineered human recombinant interleukin-33 exhibits extended half-life and enhanced binding affinity with ST2 receptor; ILC2s, group 2 innate lymphoid cells; MLP-aTIM-3, the MLP (membrane-coated lipid nanoparticle) component serves to present tumor antigens, while aTIM-3 denotes an anti-TIM-3 antibody. Table 2TLS-based therapies for clinical applications in PDACSpeciesTreatmentFindingsReferenceHumanGVAXOf 39 patients, 33 (85%) developed TLS in their tumors 2 weeks after GVAX vaccination.Lutz et al.130HumanGVAX ± nivolumabwhile GVAX vaccination induced TLS formation, it provided only limited prognostic benefit. Subsequent nivolumab combination therapy substantially augmented anti-tumor CD4+/CD8+ T cell infiltration within TLSs, correlating strongly with enhanced patient survival.Li et al.131HumanSBRTfollowing SBRT, TLSs exhibited reduced overall quantity and dimensions. However, post-treatment TLSs demonstrated preferential localization within or immediately adjacent to tumor regions. Furthermore, these residual TLSs showed significant depletion of Tregs and PD-1+ CD8+ T cells.Mills et al.133MouseH-e-rIL-33–Fcsignificantly expanded intratumoral KLRG1+ ILC2s, promoting TLS formation and suppressing tumor growth.Amisaki et al.92MouseMLP-aTIM-3the MLP-aTIM-3 nano-vaccine effectively targets exhausted T cells, restores CD8+ T cell function through TIM-3 signaling blockade, and significantly promotes TLS neogenesis and maturation within TME. This therapeutic strategy demonstrated tumor growth suppression and prolonged survival in animal models.Chen et al.132MouseCXCL13 + CCL21in orthotopic PDAC murine models, combined CXCL13/CCL21 administration promoted de novo TLS formation. This combination strategy significantly enhanced survival outcomes compared to gemcitabine monotherapy.Delvecchio et al.105GVAX, an allogeneic PDAC vaccine engineered through irradiation to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF); SBRT, stereotactic body radiotherapy; H-e-rIL-33-Fc, the engineered human recombinant interleukin-33 exhibits extended half-life and enhanced binding affinity with ST2 receptor; ILC2s, group 2 innate lymphoid cells; MLP-aTIM-3, the MLP (membrane-coated lipid nanoparticle) component serves to present tumor antigens, while aTIM-3 denotes an anti-TIM-3 antibody. TLS-based therapies for clinical applications in PDAC GVAX, an allogeneic PDAC vaccine engineered through irradiation to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF); SBRT, stereotactic body radiotherapy; H-e-rIL-33-Fc, the engineered human recombinant interleukin-33 exhibits extended half-life and enhanced binding affinity with ST2 receptor; ILC2s, group 2 innate lymphoid cells; MLP-aTIM-3, the MLP (membrane-coated lipid nanoparticle) component serves to present tumor antigens, while aTIM-3 denotes an anti-TIM-3 antibody. As discussed, pancreatic cancer subtypes exhibit differential responses to B cell-targeted therapies. Molecular subtyping classifies PDAC into adaptive-enriched and myeloid-enriched categories, with TLS induction potentially enhancing anti-tumor efficacy in the adaptive-enriched subtype.28 Similarly, RNF43-mutant PDAC patients display T/B cell-driven inflammatory microenvironments.134 However, PDAC subtype-specific responses to TLS-based therapies remain scarce, and their clinical implications are underexplored. In addition to actively exploring therapeutic strategies that promote TLS formation and maturation for anti-tumor immunity, we must consider that current neoadjuvant therapies may disrupt established TLSs. Evidence demonstrates that neoadjuvant chemotherapy/radiotherapy reduces TIB/TLS density in pancreatic cancer, potentially weakening their prognostic associations. Compared with upfront surgery, neoadjuvant chemotherapy reduces B cell infiltration, TLS positivity, average TLS area, and maturation,135,136 which has been attributed to chemotherapy cytotoxicity and dexamethasone-induced immunosuppression.104 Similarly, preoperative stereotactic radiotherapy reduces overall TLS density and dimensions. However, residual TLSs demonstrate preferential intratumoral localization.133 Notably, while TLS quantity and area show no significant prognostic association, intratumoral TLSs correlate with improved clinical outcomes compared to peripheral counterparts.100 Given the strong TLS-prognosis correlation in advanced PDAC, future strategies should balance neoadjuvant benefits against B cell immunity impairment risks, potentially combining neoadjuvant regimens with TIB-preserving approaches. Conclusions and perspectives TIBs and TLSs are pivotal immune microenvironment components in pancreatic cancer, closely correlating with tumor development, progression, and prognosis. Bregs primarily suppress anti-tumor immunity through IL-35 and IL-10 secretion, whereas preliminary evidence suggests that other B cell subsets, such as plasma cells, naive B cells, and memory B cells, also participate in intratumoral immunity. TLSs consistently correlate with improved prognosis, with emerging studies elucidating their formation, maturation, and functional mechanisms. Within the TME, complex interactions among diverse cellular and extracellular matrix components govern TIB recruitment/differentiation and TLS development. Prognostic and therapeutic strategies targeting TIBs/TLSs demonstrate substantial potential. The preceding section provides a comprehensive overview of recent advances in the study of TIBs and TLSs in PDAC. Insights derived from research on TIBs and TLSs in other malignancies, when integrated with cutting-edge technologies, hold significant promise for deepening our understanding of B cell-mediated immune mechanisms in PDAC. Given the gaps in our understanding of B cell subsets and their complex functions in the TME, emerging single-cell and spatial multi-omics and lineage-tracing technologies are enabling the precise delineation of functional heterogeneity and differentiation trajectories across distinct TIB subsets. This approach facilitates selective depletion of tumor-promoting subsets while preserving or enhancing anti-tumor B cell populations. Double-negative (DN) B cells are defined as a B cell subset characterized by the CD27−IgD− phenotype.137 Although DN B cells have recently been identified within the TME of non-small cell lung cancer and nasopharyngeal carcinoma,138,139 their role in pancreatic cancer remains uncharacterized. These cells are thought to generate antibody-secreting cells through an extrafollicular pathway and accumulate within immature TLSs, exhibiting immunosuppressive functions in the TME.29 Another structure warranting attention is HEVs, which serve as the primary site for lymphocyte entry from the bloodstream into TLSs, play a crucial role in overcoming the physical barriers within PDAC.140 By facilitating enhanced immune cell infiltration, HEVs represent a promising therapeutic target for transforming the immunologically “cold” or immune-desert TME typical of PDAC into a more immunoresponsive state.141 Importantly, dendritic cells are essential in maintaining the HEV phenotype and regulating lymphocyte homing to lymphoid tissues, primarily through LTβR-dependent signaling pathways.142 Furthermore, preclinical models have demonstrated that antiangiogenic, as well as immunomodulatory therapies and adeno-associated virus (AAV)-mediated delivery of LIGHT can promote HEV neogenesis and enhance lymphocyte infiltration and anti-tumor immune responses through LTβR signaling cascade.143,144 The third key question requiring further elucidation concerns the mechanisms of TLS formation and maturation. Although mature intratumoral TLSs correlate with favorable prognosis and treatment response, they develop infrequently in pancreatic cancer patients. Potential mechanisms underlying this rarity may involve tumor-intrinsic immune signaling and immune-stromal interactions.28 Crucially, TLS formation critically depends on fibroblast-stromal crosstalk.48 In murine melanoma, TNF-stimulated CAFs acquire LTo-like properties, collaborating with CD8+ T cells and LTα1β2+ B cells to drive TLS development.145 Similarly, in colorectal cancer liver metastases, CCL19-expressing fibroblasts recruit B cells via the CCR7 axis to promote TLS formation.146 Beyond fibroblast-stromal crosstalk, amino acid metabolism may regulate TLS maturation. For example, inhibiting tryptophan metabolism has been shown to enhance TLS maturation in hepatocellular carcinoma.147 Intriguingly, nerve fibers within the TME appear to exhibit a close spatial association with TLSs. In PDAC, approximately 50% of TLSs are localized within 100 μm of neural fibers,99 suggesting potential involvement of Schwann cells and neurotransmitters in TLS formation and function. For researchers investigating TLSs, a persistent challenge in TLS research remains the scarcity of suitable and stable experimental models. Emerging technologies such as organoid systems may provide a solution to this methodological limitation. Concurrently, single-cell sequencing and spatial transcriptomics promise deeper insights into TME component interactions governing TLS formation, with potential to alleviate PDAC immune suppression. Researchers have also improved TLS detection methods, with pathomics technology enabling quantification of TLS area proportion and classification of TLS maturity.148,149,150 High-quality detection models may enable objective TLS feature identification and standardized maturity classification criteria, facilitating clinical translation. Therapeutic strategies inducing TLS formation are emerging. Given that TLSs form in diverse tumor types, advances from other tumor types may be leveraged. In melanoma models, TNF signaling plays a central role, with exogenous TNF representing a potential approach.145 Similarly, STING agonists promote TLS development in melanoma.151 In ovarian cancer models, adoptive Tfh transfer enhances TLS formation in preclinical studies.152 Notably, targeted delivery of the cytokine LIGHT to tumor vasculature promotes TLS formation in insulinoma and Lewis lung carcinoma models.153 The gut microbiota also modulates TLS formation/maturation, offering another therapeutic target.154,155 However, as discussed in section “strategies promoting TLS formation and maturation,” since TLSs likely exert anti-tumor effects by remodeling the immune microenvironment, research should focus not only on increasing TLS abundance but also on whether they successfully reshape the TME. Meanwhile, tumor recurrence stems from inadequate local immune activation and delayed systemic responses,124 which neoadjuvant therapy/surgical resection may exacerbate by disrupting TLS-mediated immunity. Therefore, how to utilize TLSs to balance existing therapeutic measures with local anti-tumor immunity warrants further investigation. It must also be emphasized that TLSs exhibit substantial heterogeneity across different tumor types. In pan-cancer analyses, TLSs within PDAC demonstrate a notably low detection rate and are predominantly distributed in the peritumoral stroma rather than the intratumoral space.156 Comprehensive comparisons of TLS characteristics across various malignancies have been detailed in reviews by Sautès-Fridman et al.94 and Deng et al.156 Therefore, these pan-cancer comparisons provide deeper insights into the nature of TLSs within PDAC. Beyond their targeted anti-tumor effects, TLSs may generate autoreactive plasma cells due to heightened local immunity, rarely causing paraneoplastic syndromes.21,157 Other pancreatic subtypes like neuroendocrine tumors (PNETs) also warrant attention, as TLSs correlate with prognosis in nonfunctional PNETs.158 It is important to acknowledge the limitations of this review. The summaries presented in Figures and Tables regarding TLS prevalence, maturation stages, and predicted benefits from TLS-targeted therapies represent a qualitative narrative synthesis of the current literature. These generalized conclusions are intended to highlight emerging trends rather than serve as statistically pooled data from a quantitative meta-analysis and should therefore be interpreted with appropriate caution. Overall, targeting TIBs and TLSs offers a promising therapeutic strategy for pancreatic cancer. High-throughput and artificial intelligence advances will accelerate deciphering their functional roles. Acknowledgments The authors thank all colleagues and collaborators for their valuable discussions and support during the preparation of this manuscript. This study was supported by the 10.13039/501100001809National Natural Science Foundation of China (nos. 82171722, 82271764, and 82471772) and National High Level Hospital Clinical Research Funding (Interdepartmental Research Project of 10.13039/100017415Peking University First Hospital 2023IR23, 2024IR11). Author contributions Z.P. drafted this review and designed the figures; F.Z. completed the data collection and provided editorial assistance; C.Z. and X.L. gave some valuable suggestions; X.T., Y.Y., and Y.M. provided the design, revision, and funding supports for the manuscript. Declaration of interests The authors declare no competing interests.